Test Description

What is aPTT?

The Activated Partial Thromboplastin Time (aPTT) measures how long it takes blood plasma to clot after adding activators and phospholipid in the absence of tissue factor. This test specifically evaluates the intrinsic and common pathways of the coagulation cascade.

How Does the Test Work?

The aPTT test evaluates multiple clotting factors in a specific sequence:

  • Intrinsic pathway activation: Contact activation of Factor XII → Factor XIIa → activates Factor XI
  • Intrinsic cascade: Factor XIa → activates Factor IX → Factor IXa + Factor VIIIa → activates Factor X
  • Common pathway: Factor Xa + Factor Va → converts prothrombin (Factor II) to thrombin → converts fibrinogen (Factor I) to fibrin clot
  • aPTT measurement: Time from adding activator and phospholipid until visible clot forms

Understanding the Coagulation Cascade

The aPTT specifically tests the intrinsic pathway (contact activation) and common pathway:

  • Intrinsic pathway factors: XII (Hageman), XI, IX (Christmas), VIII (Antihemophilic factor)
  • Common pathway factors: X (Stuart-Prower), V (proaccelerin), II (prothrombin), I (fibrinogen)
  • Heparin mechanism: Enhances antithrombin III, which inhibits Factors IIa (thrombin), Xa, IXa, XIa → prolongs aPTT
  • Hemophilia defects: Hemophilia A (Factor VIII deficiency), Hemophilia B (Factor IX deficiency)
aPTT vs PT: PT tests the extrinsic pathway (Factor VII + tissue factor), while aPTT tests the intrinsic pathway (contact activation). The pathways converge at the common pathway (Factors X, V, II, I). Together, PT and aPTT can localize which part of the coagulation cascade is defective.

Clinical Uses of aPTT

  • Heparin monitoring: Target aPTT 1.5-2.5× control for therapeutic anticoagulation (though anti-Xa now preferred)
  • Hemophilia diagnosis: Prolonged aPTT with normal PT suggests Factor VIII or IX deficiency
  • Preoperative screening: Identifies bleeding risk before surgery (though routine screening not recommended without bleeding history)
  • Lupus anticoagulant: Paradoxically prolongs aPTT in vitro but increases clotting risk in vivo
Quick Reference
  • Normal Range: 25-35 seconds (lab-dependent; check your institution's reference range)
  • Therapeutic Heparin Range: 1.5-2.5× control (or 60-80 seconds typical)
  • Alternative Monitoring: Anti-Xa levels increasingly preferred over aPTT for heparin dosing
  • Primary Use: Monitor unfractionated heparin therapy, diagnose hemophilia and other intrinsic pathway disorders, screen for lupus anticoagulant
  • Sample Type: Citrated plasma (blue-top tube)
  • Key Point: aPTT tests intrinsic pathway (Factors VIII, IX, XI, XII) and common pathway (X, V, II, I)
Clinical Significance

Prolonged aPTT (Elevated)

An elevated aPTT indicates slower clotting through the intrinsic or common pathway. Determine if this is therapeutic (on heparin) or pathologic.

Anticoagulant Medications

  • Unfractionated heparin (UFH): Enhances antithrombin III; target aPTT 1.5-2.5× control for therapeutic effect
  • Direct thrombin inhibitors: Argatroban, bivalirudin (monitor with aPTT, target 1.5-3×)
  • Low molecular weight heparin (LMWH): Usually does NOT prolong aPTT significantly (monitor with anti-Xa if needed)
  • Warfarin: Prolongs aPTT only at high doses (PT/INR is primary monitoring test)

Hemophilia - Factor VIII or IX Deficiency

  • Hemophilia A: Factor VIII deficiency; X-linked recessive; most common severe inherited bleeding disorder (1:5000 males)
  • Hemophilia B (Christmas disease): Factor IX deficiency; X-linked recessive; clinically identical to hemophilia A
  • Severity classification:
    • Severe: <1% factor activity - spontaneous bleeding into joints/muscles
    • Moderate: 1-5% factor activity - bleeding with minor trauma
    • Mild: 5-40% factor activity - bleeding with surgery/major trauma
  • Laboratory findings: Prolonged aPTT, normal PT, low Factor VIII or IX level on specific assay

Lupus Anticoagulant - The Paradox

  • Mechanism: Antiphospholipid antibodies that bind phospholipids in the aPTT test → prolong aPTT in vitro
  • The paradox: Prolongs aPTT (suggesting bleeding risk) but INCREASES thrombosis risk in vivo
  • Clinical significance: Antiphospholipid syndrome (APS) - recurrent DVT/PE, pregnancy loss, stroke
  • Diagnosis: Prolonged aPTT that does NOT correct with 1:1 mixing study (inhibitor present) + positive lupus anticoagulant confirmatory testing
  • Association: 30-40% of SLE patients have lupus anticoagulant; can occur without SLE

Other Factor Deficiencies (Rare)

  • Factor XI deficiency: Mild bleeding tendency; common in Ashkenazi Jewish population
  • Factor XII deficiency: Markedly prolonged aPTT but NO bleeding tendency (Factor XII not essential for hemostasis)
  • von Willebrand Disease (vWD): May prolong aPTT if Factor VIII levels low (vWF stabilizes Factor VIII)

Disseminated Intravascular Coagulation (DIC)

  • Consumption coagulopathy: Both PT and aPTT prolonged
  • Laboratory panel: Prolonged PT/aPTT, low fibrinogen (<100 mg/dL), low platelets, elevated D-dimer (>4000 ng/mL)
  • Causes: Sepsis, trauma, obstetric emergencies, malignancy

Liver Disease

  • Mechanism: Liver synthesizes all clotting factors (except Factor VIII from endothelium)
  • Both PT and aPTT prolonged: Common pathway factors (II, V, X) depleted
  • PT more sensitive: Factor VII (extrinsic pathway) has shortest half-life, so PT rises earlier

Shortened aPTT (Low)

A shortened aPTT is less clinically significant than prolonged aPTT but may suggest:

  • Hypercoagulable state: Acute phase reaction with elevated Factor VIII
  • Sample issues: Activated sample, overfilled tube, clotted specimen
  • Subclinical DIC: Early consumptive coagulopathy before decompensation
Interpretation Guidelines

Approach to Prolonged aPTT

Step 1: Check PT to localize defect

Swipe to see more
PT/INR aPTT Interpretation Examples
Normal Prolonged Intrinsic pathway defect Hemophilia A/B, Factor XI deficiency, heparin, lupus anticoagulant
Prolonged Normal Extrinsic pathway defect Factor VII deficiency, early warfarin effect
Prolonged Prolonged Common pathway defect DIC, liver disease, warfarin, Factor X/V/II deficiency

Step 2: Perform 1:1 Mixing Study

Mix patient plasma 1:1 with normal pooled plasma. Recheck aPTT immediately and after 1-2 hour incubation:

  • aPTT corrects to normal: Factor deficiency (hemophilia, vitamin K deficiency)
  • aPTT remains prolonged: Inhibitor present (lupus anticoagulant, Factor VIII inhibitor, heparin contamination)

Step 3: Order Specific Factor Assays

If mixing study suggests factor deficiency:

  • Factor VIII level (hemophilia A, von Willebrand disease)
  • Factor IX level (hemophilia B)
  • Factor XI level (Factor XI deficiency)
  • von Willebrand antigen and activity (vWD)

Step 4: Lupus Anticoagulant Testing

If mixing study suggests inhibitor AND patient has thrombosis history:

  • Confirmatory lupus anticoagulant testing (dilute Russell viper venom time, hexagonal phase phospholipid assay)
  • Anticardiolipin antibodies
  • Anti-β2 glycoprotein I antibodies

Hemophilia Severity and Management

Swipe to see more
Severity Factor Level Bleeding Pattern Treatment Approach
Severe <1% Spontaneous hemarthrosis, muscle bleeds Prophylactic factor replacement 2-3×/week
Moderate 1-5% Bleeding with minor trauma On-demand treatment; consider prophylaxis
Mild 5-40% Bleeding with surgery/major trauma On-demand treatment; desmopressin for mild hemophilia A
Hemophilia Emergencies - Intracranial Hemorrhage:
  1. Treat IMMEDIATELY: Do NOT wait for confirmatory testing if hemophilia known
  2. Factor VIII/IX replacement: Target 100% factor activity (1 unit/kg raises level ~2%)
  3. Hemophilia A: Recombinant Factor VIII 50 units/kg IV bolus
  4. Hemophilia B: Recombinant Factor IX 100 units/kg IV bolus
  5. No access to factor concentrates: Fresh frozen plasma (FFP) 15-20 mL/kg, but less effective
  6. Maintain factor levels >80%: Repeat dosing every 8-12 hours for Factor VIII, every 18-24 hours for Factor IX

Heparin Dosing Based on aPTT

Weight-Based Heparin Protocol (Example):
  1. Loading dose: 80 units/kg IV bolus
  2. Initial infusion: 18 units/kg/hour
  3. Check aPTT: 6 hours after starting infusion, then 6 hours after each rate change
  4. Goal aPTT: 1.5-2.5× control (typically 60-80 seconds)
  5. Titrate:
    • aPTT <45 sec: Bolus 80 units/kg, increase rate by 4 units/kg/hr
    • aPTT 45-59 sec: Bolus 40 units/kg, increase rate by 2 units/kg/hr
    • aPTT 60-80 sec: No change (therapeutic)
    • aPTT 81-100 sec: Decrease rate by 2 units/kg/hr
    • aPTT >100 sec: Hold infusion 1 hour, decrease rate by 3 units/kg/hr

Note: Many institutions now use anti-Xa levels instead of aPTT (target 0.3-0.7 units/mL) for greater accuracy.

Interfering Factors

Medications That Prolong aPTT

  • Unfractionated heparin: Most common cause; enhances antithrombin III
  • Direct thrombin inhibitors: Argatroban, bivalirudin, dabigatran
  • Warfarin: Prolongs aPTT at high therapeutic or supratherapeutic doses
  • Rivaroxaban, apixaban: Factor Xa inhibitors; may prolong aPTT variably (not reliable for monitoring)

Pre-analytical Errors - Critical for aPTT

  • Underfilled tube: Excess citrate causes falsely prolonged aPTT - most common error
  • Overfilled tube: Insufficient citrate anticoagulation
  • Heparin contamination: Drawing from heparinized IV line or catheter → falsely prolonged aPTT
  • Clotted sample: Falsely normal or short aPTT; reject and redraw
  • Delayed processing: Should be tested within 4 hours; factors degrade over time
  • Hemolyzed sample: Can interfere with optical detection methods
  • Lipemia: Turbid sample interferes with clot detection
  • High hematocrit (>55%): Alters citrate-to-blood ratio; may require adjusted collection

Physiologic Factors

  • Lupus anticoagulant: Prolongs aPTT without bleeding risk (increases thrombosis risk)
  • Elevated Factor VIII: Acute phase reactant; may shorten aPTT slightly
  • Pregnancy: Increased Factor VIII and fibrinogen may shorten aPTT

Reagent Variability

  • Different reagents: aPTT reagents have different sensitivities to heparin, lupus anticoagulant, and factor deficiencies
  • Reference range variation: Some reagents have normal ranges 25-35 sec, others 30-40 sec
  • Institutional protocols: Therapeutic heparin targets may differ (some use 60-80 sec, others use 1.5-2.5× ratio)
Clinical Pearls
"Lupus anticoagulant is a misnomer": Despite its name, lupus anticoagulant does NOT cause bleeding and does NOT require lupus (SLE). It prolongs aPTT in the lab but INCREASES thrombosis risk in patients. Think "lupus anticoagulant = paradoxical prothrombotic antibody."
Factor XII deficiency - the harmless prolonged aPTT: Factor XII deficiency causes markedly prolonged aPTT (often 60-80 seconds) but NO bleeding tendency. Patients can undergo surgery without factor replacement. However, they ARE at risk for thrombosis. Do NOT treat prolonged aPTT without knowing the cause.
Mixing study is your friend: When aPTT is prolonged and you don't know why, the 1:1 mixing study quickly narrows the differential. Correction = factor deficiency (give replacement). No correction = inhibitor present (lupus anticoagulant or acquired hemophilia).
Heparin contamination is common: Never draw coagulation studies from a heparinized line or catheter. Even tiny amounts of heparin (from line flushing) cause falsely prolonged aPTT. Always draw from a clean peripheral stick or discard the first 5-10 mL from a central line.
Anti-Xa replacing aPTT for heparin monitoring: aPTT has high inter-laboratory variability and poor correlation with heparin levels. Anti-Xa assays (target 0.3-0.7 units/mL) are more accurate and reproducible. Many ICUs and anticoagulation services now use anti-Xa exclusively.
Hemophilia A vs B - clinically identical: You cannot distinguish hemophilia A (Factor VIII deficiency) from hemophilia B (Factor IX deficiency) by clinical presentation or aPTT. Both cause identical bleeding patterns and prolonged aPTT. Specific factor assays are required for diagnosis. Treatment differs (Factor VIII vs Factor IX concentrates).
Desmopressin (DDAVP) for mild hemophilia A: DDAVP releases stored Factor VIII from endothelial cells, raising levels 2-4 fold. Useful for mild hemophilia A (baseline 5-40%) before minor procedures or bleeding. Does NOT work for hemophilia B (Factor IX) or severe hemophilia A (<1% baseline).
Acquired hemophilia - rare but deadly: Elderly patients can develop acquired Factor VIII inhibitors (autoantibodies). Presents as spontaneous bleeding in previously healthy person. aPTT markedly prolonged, does NOT correct with mixing study. Treat with bypassing agents (Factor VIIa, aPCC) + immunosuppression. High mortality (10-20%).
LMWH does NOT require monitoring: Low molecular weight heparins (enoxaparin, dalteparin) have predictable pharmacokinetics and do NOT prolong aPTT significantly at therapeutic doses. No routine monitoring needed. If monitoring required (renal failure, obesity, pregnancy), use anti-Xa levels, NOT aPTT.
References
  1. Kratz, A., Ferraro, M., Sluss, P. M., & Lewandrowski, K. B. (2004). Laboratory reference values. New England Journal of Medicine, 351, 1548-1564.
  2. Lee, M. (Ed.). (2009). Basic skills in interpreting laboratory data. Ashp.
  3. Farinde, A. (2021). Lab values, normal adult: Laboratory reference ranges in healthy adults. Medscape. https://emedicine.medscape.com/article/2172316-overview?form=fpf
  4. Nickson, C. (n.d.). Critical Care Compendium. Life in the Fast Lane • LITFL. https://litfl.com/ccc-critical-care-compendium/
  5. Farkas, Josh MD. (2015). Table of Contents - EMCrit Project. EMCrit Project. https://emcrit.org/ibcc/toc/
Back to Coagulation Panel All Lab Values
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
The clinical content and references are curated and reviewed by myself; however, AI was used to assist in organizing, paraphrasing, and formatting the information presented.